These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 22549810)
1. Endocrine disrupting chemicals promote the growth of ovarian cancer cells via the ER-CXCL12-CXCR4 signaling axis. Hall JM; Korach KS Mol Carcinog; 2013 Sep; 52(9):715-25. PubMed ID: 22549810 [TBL] [Abstract][Full Text] [Related]
2. Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Hall JM; Korach KS Mol Endocrinol; 2003 May; 17(5):792-803. PubMed ID: 12586845 [TBL] [Abstract][Full Text] [Related]
3. Differential estrogen-regulation of CXCL12 chemokine receptors, CXCR4 and CXCR7, contributes to the growth effect of estrogens in breast cancer cells. Boudot A; Kerdivel G; Habauzit D; Eeckhoute J; Le Dily F; Flouriot G; Samson M; Pakdel F PLoS One; 2011; 6(6):e20898. PubMed ID: 21695171 [TBL] [Abstract][Full Text] [Related]
4. Bisphenol AF stimulates transcription and secretion of C-X-C chemokine ligand 12 to promote proliferation of cultured T47D breast cancer cells. Li M; Han X; Gao W; Chen F; Shao B Toxicology; 2015 Dec; 338():30-6. PubMed ID: 26435001 [TBL] [Abstract][Full Text] [Related]
5. Genistein suppressed epithelial-mesenchymal transition and migration efficacies of BG-1 ovarian cancer cells activated by estrogenic chemicals via estrogen receptor pathway and downregulation of TGF-β signaling pathway. Kim YS; Choi KC; Hwang KA Phytomedicine; 2015 Oct; 22(11):993-9. PubMed ID: 26407941 [TBL] [Abstract][Full Text] [Related]
6. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro. Liu Y; Ren CC; Yang L; Xu YM; Chen YN J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987 [TBL] [Abstract][Full Text] [Related]
8. Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway. Sauvé K; Lepage J; Sanchez M; Heveker N; Tremblay A Cancer Res; 2009 Jul; 69(14):5793-800. PubMed ID: 19584281 [TBL] [Abstract][Full Text] [Related]
9. Androgen Triggers the Pro-Migratory CXCL12/CXCR4 Axis in AR-Positive Breast Cancer Cell Lines: Underlying Mechanism and Possible Implications for the Use of Aromatase Inhibitors in Breast Cancer. Azariadis K; Kiagiadaki F; Pelekanou V; Bempi V; Alexakis K; Kampa M; Tsapis A; Castanas E; Notas G Cell Physiol Biochem; 2017; 44(1):66-84. PubMed ID: 29131020 [TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of 3,3'-diindolylmethane on epithelial-mesenchymal transition induced by endocrine disrupting chemicals in cellular and xenograft mouse models of breast cancer. Lee GA; Hwang KA; Choi KC Food Chem Toxicol; 2017 Nov; 109(Pt 1):284-295. PubMed ID: 28844962 [TBL] [Abstract][Full Text] [Related]
11. Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk. Rhodes LV; Antoon JW; Muir SE; Elliott S; Beckman BS; Burow ME Mol Cancer; 2010 Nov; 9():295. PubMed ID: 21087507 [TBL] [Abstract][Full Text] [Related]
12. Cell growth of BG-1 ovarian cancer cells is promoted by di-n-butyl phthalate and hexabromocyclododecane via upregulation of the cyclin D and cyclin-dependent kinase-4 genes. Park MA; Hwang KA; Lee HR; Yi BR; Jeung EB; Choi KC Mol Med Rep; 2012 Mar; 5(3):761-6. PubMed ID: 22179484 [TBL] [Abstract][Full Text] [Related]
13. Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer. Mao TL; Fan KF; Liu CL Gene Ther; 2017 Oct; 24(10):621-629. PubMed ID: 28753202 [TBL] [Abstract][Full Text] [Related]
14. [Effect of chemokine CXCL12 and its receptor CXCR4 on proliferation, migration and invasion of epithelial ovarian cancer cells]. Jiang YP; Wu XH; Xing HY; DU XY Zhonghua Fu Chan Ke Za Zhi; 2007 Jun; 42(6):403-7. PubMed ID: 17697603 [TBL] [Abstract][Full Text] [Related]
15. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4. Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961 [TBL] [Abstract][Full Text] [Related]
16. Abortifacient metapristone (RU486 derivative) interrupts CXCL12/CXCR4 axis for ovarian metastatic chemoprevention. Zheng N; Chen J; Li T; Liu W; Liu J; Chen H; Wang J; Jia L Mol Carcinog; 2017 Aug; 56(8):1896-1908. PubMed ID: 28277622 [TBL] [Abstract][Full Text] [Related]
17. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer. Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564 [TBL] [Abstract][Full Text] [Related]
18. Notch pathway promotes ovarian cancer growth and migration via CXCR4/SDF1α chemokine system. Chiaramonte R; Colombo M; Bulfamante G; Falleni M; Tosi D; Garavelli S; De Simone D; Vigolo E; Todoerti K; Neri A; Platonova N Int J Biochem Cell Biol; 2015 Sep; 66():134-40. PubMed ID: 26235278 [TBL] [Abstract][Full Text] [Related]
19. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Obermajer N; Muthuswamy R; Odunsi K; Edwards RP; Kalinski P Cancer Res; 2011 Dec; 71(24):7463-70. PubMed ID: 22025564 [TBL] [Abstract][Full Text] [Related]
20. Induced growth of BG-1 ovarian cancer cells by 17β-estradiol or various endocrine disrupting chemicals was reversed by resveratrol via downregulation of cell cycle progression. Kang NH; Hwang KA; Kim TH; Hyun SH; Jeung EB; Choi KC Mol Med Rep; 2012 Jul; 6(1):151-6. PubMed ID: 22552626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]